Molecular characterization of glioblastoma cell differentiation

Neurosurgery

Volumn 41, Issue 4, 1997, Pages 886-897

  Engelhard, Herbert H ^a,b   Duncan, Holly A ^a   Dal Canto, Mauro ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Neurosurgery   (United States)

Author keywords

C myc protein; Cellular differentiation; Flow cytometry; Glial fibrillary acidic protein; Glioblastoma multiforme; Sodium butyrate

Indexed keywords

BUTYRIC ACID; CELL PROTEIN; GLIAL FIBRILLARY ACIDIC PROTEIN; ONCOPROTEIN;

ARTICLE; CELL CYCLE; CELL DIFFERENTIATION; CELL STRUCTURE; FLOW CYTOMETRY; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOBLOTTING; NORTHERN BLOTTING; ONCOGENE C MYC; PRIORITY JOURNAL;

BRAIN NEOPLASMS; BUTYRIC ACID; BUTYRIC ACIDS; CELL DIFFERENTIATION; CELL DIVISION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIAL FIBRILLARY ACIDIC PROTEIN; GLIOBLASTOMA; HUMANS; IMMUNOENZYME TECHNIQUES; NEOPLASM PROTEINS; PROTO-ONCOGENE PROTEINS C-MYC; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 0030766571     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006123-199710000-00023     Document Type: Article

References (110)

1. Appley AJ, Fitzgibbons PL, Chandrasoma PT, Hinton DR, Apuzzo MLJ: Multiparameter flow cytometric analysis of neoplasms of the central nervous system: Correlation of nuclear antigen p105 and DNA content with clinical behavior. Neurosurgery 27:83-96, 1990.
2. Balasingam V, Tejeda-Berges T, Wright E, Bouckova R, Yong VW: Reactive astrogliosis in the neonatal mouse brain and its modulation by cytokines. J Neurosci 14:846-856, 1994.
3. Beere HM, Hickman JA: Differentiation: A suitable strategy for cancer chemotherapy? Anticancer Drug Des 8:299-322, 1993.
4. Bianchi Scarra GL, Romani M, Coviello DA, Carre C, Ravazzolo R, Vidali G, Ajmar F: Terminal erythroid differentiation in the K-562 cell line by 1-B-D-arabinofuranosylcytosine: Accompaniment by c-myc messenger RNA decrease. Cancer Res 46:6327-6332, 1986.
5. Bignami A, Dahl D, Rueger DC: Glial fibrillary acidic (GFA) protein in normal neural cells and in pathological conditions, in Advances in Cellular Neurobiology. New York, Academic Press, 1980, vol 1, pp 285-310.
6. Bongcam-Rudloff E, Nister M, Betsholtz C, Wang JL, Stenman G, Huebner K, Croce CM, Westermark B: Human glial fibrillary acidic protein: Complementary DNA cloning, chromosome localization, and messenger RNA expression in human glioma cell lines of various phenotypes. Cancer Res 51:1553-1560, 1991.
7. Bonnin JM, Rubinstein LJ: Immunohistochemistry of central nervous system tumors: Its contributions to neurosurgical diagnosis. J Neurosurg 60:1121-1133, 1984.
8. Brenner M: Structure and transcriptional regulation of the GFAP gene. Brain Pathol 4:245-257, 1994.
9. Brodie C, Goldreich N: Interleukin-4 modulates the proliferation and differentiation of glial cells. J Neuroimmunol 55:91-97, 1994.
10. Bruce-Gregorios JH, Soucy DM, Chen MG, Norenberg MD: Effect of methotrexate on glial fibrillary acidic protein content of astrocytes in primary culture. J Neuropathol Exp Neurol 50:118-125, 1991.
11. Bullard DE, Bigner SH, Bigner DD: The morphologic response of cell lines derived from human gliomas to dibutyryl adenosine 3′:5′-cyclic monophosphate. J Neuropathol Exp Neurol 40:230-246, 1981.
12. Byrd JC, Alho H: Differentiation of PC12 pheochromocytoma cells by sodium butyrate. Dev Brain Res 31:151-155, 1987.
13. Canady KS, Ali-Osman F, Rubel EW: Extracellular potassium influences DNA and protein syntheses and glial fibrillary protein expression in cultured glial cells. Glia 3:368-374, 1990.
14. Chavany C, Connell Y, Neckers L: Contribution of sequence and phosphorothioate content to inhibition of cell growth and adhesion caused by c-myc antisense oligomers. Mol Pharmacol 48: 738-746, 1995.
15. Cook AW, Carter WA, Nidzgorski F, Akhtar L: Human brain tumor-derived cell lines: Growth rate reduced by human fibroblast interferon. Science 219:881-883, 1982.
16. Danova M, Giaretti W, Merlo F, Mazzini G, Gaetani P, Geido E, Gentile S, Butti G, DiVinci A, Riccardi A: Prognostic significance of nuclear DNA content in human neuroepithelial tumors. Int J Cancer 48:663-667, 1991.
17. Dean PN, Jett JH: Mathematical analysis of DNA distributions derived from flow microfluorometry. J Cell Biol 60:523-527, 1974.
18. Dent GA, Ayscue LH, High KA, Leglise MC, Ross DW: Flow cytometric correlation of the c-myc oncoprotein and cell cycle kinetics of HL-60 leukaemia during induced maturation with cytosine arabinoside and dimethylsulphoxide. Cell Tissue Kinet 22:1-11, 1988.
19. Dent GA, Leglise MC, Pryzwansky KB, Ross DW: Simultaneous paired analysis by flow cytometry of surface markers, cytoplasmic antigens, or oncogene expression with DNA content. Cytometry 10:192-198, 1989.
20. Dexter DL, Gross JL: Preclinical models for differentiation therapy, in Kornblith PL, Walker MD (eds): Advances in Neuro-Oncology. New York, Futura Publishing, Inc., 1988, pp 471-490.
21. Dexter DL, Lev R, McKendall GR, Mitchell P, Calabres P: Sodium butyrate-induced alteration of growth properties and glycogen levels in cultured human colon carcinoma cells. Histochem J 16:137-149, 1984.
22. Drexler HG, Quentmeier H, MacLeod RA, Uphoff CC, Hu ZB: Leukemia cell lines: In vitro models for the study of acute promyelocytic leukemia. Leuk Res 19:681-691, 1995.
23. Duffy PE: Astrocytes: Normal, Reactive, and Neoplastic. New York, Raven Press, 1983, pp 25-30.
24. Duffy PE, Graf L, Rapport MM: Identification of glial fibrillary acidic protein by the immunoperoxidase method in human brain tumors. J Neuropathol Exp Neurol 36:645-652, 1977.
25. Duffy PE, Huang Y-Y, Rapport MM, Graf L: Glial fibrillary acidic protein in giant cell tumors of brain and other gliomas. Acta Neuropathol (Berl) 52:51-57, 1980.
26. Ebert PS, Salcman M: Differentiation therapy is potentiated by chemotherapy and hyperthermia in human and canine brain tumor cells in vitro. Neurosurgery 34:657-664, 1994.
27. Edstrom A, Kanje M, Walum E: Effects of dibutyryl cyclic AMP and prostaglandin E1 on cultured human glioma cells. Exp Cell Res 85:217-223, 1974.
28. Eng LF, Ghirnikar RS: GFAP and astrogliosis. Brain Pathol 4:229-237, 1994.
29. Eng LF, Rubinstein LJ: Contribution of immunohistochemistry to diagnostic problems of human cerebral tumors. J Histochem Cytochem 26:513-522, 1978.
30. Engelhard HH: c-myc protein expression in relation to the proliferation and differentiation of human tumor cells. Northwestern University, 1990 (dissertation).
31. Engelhard HH: A quantitative analysis of modulations occurring in cellular c-myc protein content, %S phase and growth balance under growth-inhibitory conditions. Cell Mol Biol 39:607-620, 1993.
32. Engelhard HH: Flow cytometric applications of sulphorhodamine 101 as a fluorescent stain for total cellular protein. Biotechnic Histochem 72:1-8, 1997.
33. Engelhard HH, Seidenfeld J: Glia maturation factor causes morphological differentiation of human glioblastoma cells in vitro. J Cell Biol 99:154A, 1984 (abstr).
34. Engelhard HH, Butler AB, Bauer KD: Quantification of the c-myc oncoprotein in human glioblastoma cells and tumor tissue. J Neurosurg 71:224-232, 1989.
35. Engelhard HH, Homer RJ, Duncan HA, Rozental J: Inhibitory effects of phenylbutyrate on the proliferation, morphology, migration and invasiveness of malignant glioma cells. J Neurooncol (in press).
36. Engelhard HH, Krupka JL, Bauer KD: Simultaneous quantification of c-myc oncoprotein, total cellular protein and DNA content using multiparameter flow cytometry. Cytometry 12:68-76, 1991.
37. Engelhard HH, Wolters M, Criswell PS: Analysis of c-erbB2 protein content of human glioma cells and tumor tissue. J Neurooncol 23:31-40, 1995.
38. Fallon RJ, Cox RP: Cell cycle analysis of sodium butyrate and hydroxyurea, inducers of ectopic hormone production in HeLa cells. J Cell Physiol 100:251-262, 1979.
39. Fantini J, Guo XJ, Marvaldi J, Rougon G: Suramin inhibits proliferation of rat glioma cells and alters N-CAM cell surface expression. Int J Cancer 45:554-561, 1990.
40. Fischer I, Nolan CE, Shea TB: Effects of retinoic acid on expression of the transformed phenotype in C6 glioma cells. Life Sci 41:463-470, 1987.
41. Fukuyama K, Matsuzawa K, Hubbard SL, Dirks PB, Murakami M, Rutka JT: Analysis of glial fibrillary acidic protein gene methylation in human malignant gliomas. Anticancer Res 16: 1251-1257, 1996.
42. Giangaspero F, Chieco P, Lisignoli G, Burger PC: Comparison of cytologic composition with microfluorometric DNA analysis of the glioblastoma multiforme and anaplastic astrocytoma. Cancer 60:59-65, 1987.
43. Gowda SD, Koler RD, Bagby GC Jr: Regulation of c-myc expression during growth and differentiation of normal and leukemic human myeloid progenitor cells. J Clin Invest 77:271-278, 1986.
44. Gregorios JB, Mozes LW, Norenberg LB, Norenberg MD: Morphologic effects of ammonia on primary astrocyte cultures: Part I - Light microscopic studies. J Neuropathol Exp Neurol 44:397-403, 1985.
45. Gum JR, Kam WK, Byrd JC, Hicks JW, Sleisenger MH, Kim YS: Effects of sodium butyrate on human colonie adenocarcinoma cells: Induction of placental-like alkaline phosphatase. J Biol Chem 262:1092-1097, 1987.
46. Hargreaves AJ, Yusta B, Avila J, Hesketh JE, Aranda A, Pascual A: Sodium butyrate induces major morphological changes in C6 glioma cells that are correlated with an increased synthesis of a spectrin-like protein. Dev Brain Res 45:291-295, 1989.
47. Hayashi M, Okabe-Kado J, Hozumi M: A new experimental model for in vivo studies on differentiation and proliferation of leukemic cells using a mouse myeloid leukemia aneuploid line. Leuk Res 13:989-999, 1989.
48. High KA, Stolle CA, Schneider JW, Hu W, Benz EJ Jr: C-myc gene activation during induced maturation of HL-60 cells. J Clin Invest 79:93-99, 1987.
49. Higuchi M, Ohnishi T, Arita N, Hiraga S, Hayakawa T: Expression of tenascin in human gliomas: Its relation to histological malignancy, tumor dedifferentiation and angiogenesis. Acta Neuropathol (Berl) 85:481-487, 1993.
50. Hino A, Imahori Y, Tenjin H, Mizukawa N, Ueda S, Hirakawa K, Nakahashi H: Metabolic and hemodynamic aspects of peritumoral low-density areas in human brain tumor. Neurosurgery 26:615-621, 1990.
51. Hoyt JW, Gown AM, Kim DK, Berger MS: Analysis of proliferative grade in glial neoplasms using antibodies to the Ki-67 defined antigen and PCNA in formalin fixed, deparaffinized tissues. J Neurooncol 24:163-169, 1995.
52. Hutt-Taylor SR, Harnish D, Richardson M, Ishizaka T, Kenbury JA: Sodium butyrate and a T lymphocyte cell line-derived differentiation factor induce basophilic differentiation of the human promyelocytic leukemia cell line HL-60. Blood 71:209-215, 1988.
53. Ibayashi N, Herman MM, Boyd JC, Rubinstein LJ: Relationship of invasiveness to proliferating activity and to cytoskeletal protein production in human neuroepithelial tumors maintained in an organ culture system: Use of human cortex and dura as supporting matrices. Neurosurgery 26:629-637, 1990.
54. Ito M, Nagashima T, Hoshino T: Quantitation and distribution analysis of glial fibrillary acidic protein in human glioma cells in culture. J Neuropathol Exp Neurol 48:560-567, 1989.
55. Iwasaki K, Rogers LR, Barnett GH, Estes ML, Barna BP: Effect of recombinant tumor necrosis factor-alpha on three-dimensional growth, morphology, and invasiveness of human glioblastoma cells in vitro. J Neurosurg 78:952-958, 1993.
56. Karpel R, Sternfeld M, Ginzberg D, Guhl E, Graessmann A, Soreq H: Overexpression of alternative human acetylcholinesterase forms modulates process extensions in cultured glioma cells. J Neurochem 66:114-123, 1996.
57. King I, Mella SL, Sartorelli AC: A sensitive method to quantify the terminal differentiation of cultured epidermal cells. Exp Cell Res 167:252-256, 1986.
58. Korosue K, Takeshita I, Mannoji H, Fukui M: Interferon effects on multiplication, cytoplasmic protein and GFAP content, and morphology in human glioma cells. J Neurooncol 1:69-76, 1983.
59. Kosaka M, Nishina Y, Takeda M, Matsumoto K, Nishimune Y: Reversible effects of sodium butyrate on the differentiation of F9 embryonal carcinoma cells. Exp Cell Res 192:46-51, 1991.
60. Kruh J: Effects of sodium butyrate, a new pharmacological agent, on cells in culture. Mol Cell Biochem 42:65-82, 1982.
61. Langdon SP, Hawkes MM, Hay FG, Lawrie SS, Schol DJ, Hilgers J, Leonard RCF, Smyth JF: Effect of sodium butyrate and other differentiation inducers on poorly differentiated human ovarian adenocarcinoma cell lines. Cancer Res 48:6161-6165, 1988.
62. Li X-N, Du Z-W, Huang Q: Modulation effects of hexamethylene bisacetamide on growth and differentiation of cultured human malignant glioma cells. J Neurosurg 84:831-838, 1996.
63. Liepelt U, Kindler-Rohrborn A, Lennartz K, Reinhardt-Maelicke S, Rajewsky MF: Differentiation potential of a monoclonal antibody-defined neural progenitor cell population isolated from prenatal rat brain by fluorescence-activated cell sorting. Dev Brain Res 51:267-278, 1990.
64. Linskey ME, Gilbert MR: Glial differentiation: A review with implications for new directions in neuro-oncology. Neurosurgery 36:1-22, 1995.
65. Marushige Y, Raju NR, Marushige K, Koestner A: Modulation of growth and of morphological characteristics in glioma cells by nerve growth factor and glia maturation factor. Cancer Res 47:4109-4115, 1987.
66. Mayol X, Garriga J, Grana X: Cell cycle-dependent phosphorylation of the retinoblastoma-related protein p130. Oncogene 11: 801-808, 1995.
67. McCachren SS Jr, Nichols J, Kaufman RE, Niedel JE: Dibutyryl cyclic adenosine monophosphate reduces expression of c-myc during HL-60 differentiation. Blood 68:412-416, 1986.
68. Mechti N, Piechaczyk M, Blanchard JM, Marty L, Bonnieu A, Jeanteur P, Lebleu B: Transcriptional and post-transcriptional regulation of c-myc expression during the differentiation of murine erythroleukemia Friend cells. Nucleic Acids Res 14:9653-9666, 1986.
69. Merzak A, Raynal S, Rogers JP, Lawrence D, Pilkington GJ: Human wild type p53 inhibits cell proliferation and elicits dramatic morphological changes in human glioma cell lines in vitro. J Neurol Sci 127:125-133, 1994.
70. Michaeli J, Rifkind RA, Marks PA: Differentiating agents in cancer therapy, in Pinedo HM, Longo DL, Chabner BA (eds): Cancer Chemotherapy and Biological Response Modifiers Annual 13. New York, Elsevier Science Publishers, 1992, pp 286-307.
71. Miyake T, Okada M, Kitamura T: Reactive proliferation of astrocytes studied by immunohistochemistry for proliferating cell nuclear antigen. Brain Res 590:300-302, 1992.
72. Mori Y, Akedo H, Tanigaki Y, Tanaka KM, Okada M, Nakamura N: Effect of sodium butyrate on the production of serotonin, histamine and glycosaminoglycans by cultured murine mastocytoma cells. Exp Cell Res 127:465-470, 1980.
73. Morkve O, Halvorsen OJ, Stangeland L, Gulsvik A, Laerum OD: Quantitation of biological tumor markers (p53, c-myc, Ki-67 and DNA ploidy) by multiparameter flow cytometry in non-small-cell lung cancer. Int J Cancer 52:851-855, 1992.
74. Nelson RB, Siman R: Thrombin and its inhibitors regulate morphological and biochemical differentiation of astrocytes. Brain Res Brain Res Rev 54:93-104, 1990.
75. Newmark HL, Young CW: Butyrate and phenylacetate as differentiating agents: Practical problems and opportunities. J Cell Biochem 22[Suppl]:247-253, 1995.
76. Nicolaiew N, Dautry F: Growth stimulation of rat primary embryo fibroblasts by the human myc gene. Exp Cell Res 166:357-369, 1986.
77. Nishiguchi DJ, Stephens RE, Yates AJ: Application of flow cytometry to analyses of cultured human glioma and fetal brain cells. J Neuropathol Exp Neurol 44:254-267, 1985.
78. 31P NMR for non-invasive evaluation of tumor metabolic status. Int J Radiat Oncol Biol Phys 12:793-799, 1986.
79. Orian JM, Vasilopoulos K, Yoshida S, Kaye AH, Chow CW, Gonzales MF: Overexpression of multiple oncogenes related to histological grade of astrocytic glioma. Br J Cancer 66:106-112, 1992.
80. Philippe J, Drucker DJ, Chick WL, Habener JF: Transcriptional regulation of genes encoding insulin, glucagon, and angiotensinogen by sodium butyrate in a rat islet cell line. Mol Cell Biol 7:560-563, 1987.
81. Piepmeier JM: Observations on the current treatment of low-grade astrocytic tumors of the cerebral hemispheres. J Neurosurg 67:177-181, 1987.
82. Piepmeier JM, Keefe DL, Weinstein MA, Yoshida D, Zielinski J, Lin TT, Chen Z, Naftolin F, Phil D: Estramustine and estrone analogs rapidly and reversibly inhibit deoxyribonucleic acid synthesis and alter morphology in cultured human glioblastoma cells. Neurosurgery 32:422-431, 1993.
83. Rabson AR: Flow cytometry in the diagnosis of brain tumors. Neurosurg Clin N Am 5:135-146, 1994.
84. Rupec RA, Baeuerle PA: The genomic response of tumor cells to hypoxia and reoxygenation: Differential activation of transcription factors AP-1 and NF-kappa B. Eur J Biochem 234:632-640, 1995.
85. Rutka JT, Giblin JR, Apodaca G, De Armond SJ, Stern R, Rosenblum ML: Inhibition of growth and induction of differentiation in a malignant human glioma cell line by normal leptomeningeal extracellular matrix proteins. Cancer Res 47:3515-3522, 1987.
86. Rutka JT, Hubbard SL, Fukuyama K, Matsuzawa K, Dirks PB, Becker LE: Effects of antisense glial fibrillary acidic protein complementary DNA on the growth, invasion, and adhesion of human astrocytoma cells. Cancer Res 54:3267-3272, 1994.
87. Ryken TC, Turner JW, Hicklin DJ, Miller JF, Baggenstoss BA, Lim R: Induction of cytoskeletal alterations in C6 glioma cells by glia maturation factor. Int J Dev Neurosci 5:215-225, 1987.
88. Sachs L: Regulators of growth, differentiation, and the reversion of malignancy, in Wahren B (ed): Molecular Biology of Tumor Cells. New York, Raven Press, 1985, pp 257-280.
89. Samid D, Shack S, Myers CE: Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate. J Clin Invest 91:2288-2295, 1993.
90. Sartorelli AC: Malignant cell differentiation as a potential therapeutic approach. Br J Cancer 52:293-302, 1985.
91. Schiffer D, Giordana MT, Germano I, Mauro A: Anaplasia and heterogeneity of GFAP expression in gliomas. Tumori 72:163-170, 1986.
92. Scott RE, Edens M, Estervig DN, Filipak M, Hoerl BJ, Hsu BM, Maercklein PB, Minoo P, Tzen C-Y, Wilke MR, Zschunke MA: Cellular differentiation and the prevention and treatment of cancer, in Waxman S, Rossi GB, Takaku F (eds): The Status of Differentiation Therapy of Cancer. New York, Raven Press, 1987, pp 3-16.
93. Silvennoinen O, Hurme M: Growth inhibition caused by serum depletion induces differentiation, interleukin 1 receptor expression and interleukin 1 responsiveness in the HL-60 promyelocytic leukemia cell line. Biochem Biophys Res Commun 168: 959-965, 1990.
94. Soffietti R, Chio A, Giordana MT, Vasario E, Schiffer D: Prognostic factors in well-differentiated cerebral astrocytomas in the adult. Neurosurgery 24:686-692, 1989.
95. Spaar FW, Spaar U: DNA in human glioblastomas: A flow-fluorescence cytometrical examination in 96 tumors. Neurosurg Rev 13:123-139, 1990.
96. Stewart CC: Flow cytometric analysis of oncogene expression in human neoplasias. Arch Pathol Lab Med 113:634-640, 1989.
97. Stewart CC: Clinical applications of flow cytometry: Immunologic methods for measuring cell membrane and cytoplasmic antigens. Cancer 69:1543-1552, 1991.
98. Takahashi H, Parsons PG: In vitro phenotypic alteration of human melanoma cells induced by differentiating agents: Heterogeneous effects on cellular growth and morphology, enzymatic activity, and antigenic expression. Pigment Cell Res 3:223-232, 1990.
99. Takano S, Gately S, Engelhard HH, Tsanaclis AM, Brem S: Suramin inhibits glioma cell proliferation in vitro and in the brain. J Neurooncol 21:189-201, 1994.
100. Takemoto O, Yoshimine T, Hayakawa T, Fujita T, Nakajima S, Taneda M, Mogami H: Astrocytocytic proliferation in the brain adjacent to infarcted lesion: Immunohistochemical study of astroprotein (GFAP) and bromodeoxyuridine (BrdU). No To Shinkei 41:361-365, 1989.
101. Tanaka S, Nagashima T, Manaka S, Hori T, Yasumoto S: Growth suppression and astrocytic differentiation of glioma cells by interleukin-1. J Neurosurg 81:402-410, 1994.
102. Tang S-J, Ko L-W, Lee Y-HW, Wang F-F: Induction of fos and sis proto-oncogenes and genes of the extracellular matrix proteins during butyrate-induced glioma differentiation. Biochim Biophys Acta 1048:59-65, 1990.
103. Tannock IF: Experimental chemotherapy and concepts related to the cell cycle. Int J Radiat Biol 49:335-355, 1986.
104. Taylor CW, Kim YS, Childress-Fields KE, Yeoman LC: Sensitivity of nuclear c-myc levels and induction to differentiation-inducing agents in human colon tumor cell lines. Cancer Lett 62:95-105, 1992.
105. Thibault A, Samid D, Cooper MR, Figg WD, Tompkins AC, Patronas N, Headlee DJ, Kohler DR, Venzon DJ, Myers CE: Phase I study of phenylacetate administered twice daily to patients with cancer. Cancer 75:2932-2938, 1995.
106. Toscani A, Soprano DR, Soprano KJ: Molecular analysis of sodium butyrate-induced growth arrest. Oncogene Res 3:223-238, 1988.
107. U HS, Espiritu OD, Kelley PY, Klauber MR, Hatton JD: The role of epidermal growth factor receptor in human gliomas: Part II - The control of glial process extension and the expression of glial fibrillary acidic protein. J Neurosurg 82:847-857, 1995.
108. Yasue M, Tomita T, Engelhard H, Gonzalez-Crussi F, McLone D, Bauer K: Prognostic importance of DNA ploidy in medulloblastoma of childhood. J Neurosurg 70:385-391, 1989.
109. Yen A, Forbes ME: c-myc down regulation and precommitment in HL-60 cells due to bromodeoxyuridine. Cancer Res 50:1411-1420, 1990.
110. Yen A, Varvayanis S: The ratio of retinoblastoma (RB) to fos and RB to myc expression during the cell cycle. Proc Soc Exp Biol Med 210:205-212, 1995.